|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
1996-6-13
|
|
pubmed:abstractText |
In patients with chronic hepatitis B, treatment with interferon alfa and the consequent loss of hepatitis B e antigen (HBeAg) from the blood leads to a reduction in inflammatory activity, but the clinical benefits of this treatment have not been established. We evaluated whether HBeAg seroconversion induced by interferon alfa improves clinical outcome.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
30
|
|
pubmed:volume |
334
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1422-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8618580-Antiviral Agents,
pubmed-meshheading:8618580-DNA, Viral,
pubmed-meshheading:8618580-Hepatitis, Chronic,
pubmed-meshheading:8618580-Hepatitis B,
pubmed-meshheading:8618580-Hepatitis B Surface Antigens,
pubmed-meshheading:8618580-Hepatitis B e Antigens,
pubmed-meshheading:8618580-Hepatitis B virus,
pubmed-meshheading:8618580-Humans,
pubmed-meshheading:8618580-Interferon-alpha,
pubmed-meshheading:8618580-Prospective Studies,
pubmed-meshheading:8618580-Recombinant Proteins,
pubmed-meshheading:8618580-Survival Analysis,
pubmed-meshheading:8618580-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
|
|
pubmed:affiliation |
Department of Medicine, Heinrich Heine University Düsseldorf, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
